We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Horizon, Axol Announce Partnership

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

The relationship brings together Horizon’s precision genome editing capability and Axol’s expertise in iPSC reprogramming and differentiation to provide isogenic cell lines for neuronal and cardiovascular disease research. Both companies will jointly market and sell the products and services derived from the partnership.  

Initially, Horizon and Axol will work together to generate matched isogenic pairs of normal and diseased models, encompassing clinically relevant mutations. The originating iPSCs will be derived from a number of patient genetic backgrounds and then selectively modified into neuronal or cardiac cells to examine the effects of the changes. These renewable isogenic cell lines will be the first of their kind in the neuronal space. Custom requests to customer specifications will also be accepted.   

“iPSCs are becoming a key component of neuronal and cardiovascular research due to their stability as compared with primary cells, and hence the ability to perform genomic modifications on them,” commented Eric Rhodes, Chief Technology Officer, Horizon Discovery. “The partnership with Axol and resulting isogenic cell lines will offer the ability to assess the effects of disease specific mutations against a fixed genetic background, for the first time in these disease areas.”

Sanj Kumar, Chief Business Officer, Axol Bioscience, said: “This partnership builds on Axol’s strong position in the use of stem cell technology, and the combination of Horizon’s gene editing expertise with Axol’s experience in working with iPSCs will offer valuable new tools for researchers.” 

The partnership has the potential to be extended to a wide range of different disease areas and cell phenotypes. Financial terms are not disclosed.